The Toxicity of Iodinated Radiographic Contrast Agents in the Clinical Practice

Iodinated radiographic contrast agents (IRCA) are pharmaceutical agents used to improve the visibility of internal organs and structures in X-ray based imaging techniques. However, IRCA may have adverse unwanted effects, ranging from a mild inconvenience, such as itching, to a life-threatening emergency. The adverse effects of IRCA include delayed allergic reactions, anaphylactic reactions, and/or cutaneous reactions. But exposure to IRCA may be associated also with the development of either hyperthyroidism or hypothyroidism, presumably due to the effect of free, biologically active elemental iodine ions present in these agents. Among the side effects associated with the use of intravascular injection of IRCA, Contrast-induced nephropathy (CIN) is undoubtedly their most important and frequent well known adverse reaction. The pathogenesis of CIN is discussed in detail including the factors that increase the incidence of CIN, the main ones being pre-existing renal impairment, particularly when associated with diabetes mellitus. Finally, the measures to reduce the nephrotoxicity of IRCA are suggested beginning with monitoring renal function, discontinuation of potentially nephrotoxic drugs, use of either iodixanol or iopamidol at the lowest dosage possible. The main procedure for prevention of CIN is an adequate hydration of the patient with either isotonic sodium chloride or sodium bicarbonate solutions. A long list of references is provided that will enable readers a deep appreciation of the topic. DOI : 10.14302/issn.2574-4488.jna-14-601 Corresponding Author: Michele Andreucci, MD, PhD, Associate Professor of Nephrology, “Magna Graecia” University, I-88100 Catanzaro, Italy, E-mail: andreucci@unicz.it


Side effects of iodinated radiographic contrast agents (IRCA)
We know that any pharmaceutical agent, in addition to having a useful effect, may also be responsible for side effects that may be minor and acceptable or severe and even dangerous.As IRCA have no therapeutic effects, the ideal agent should be able to provide optimal imaging quality without substantial adverse reactions at the same time [3].But IRCA, in addition to their common usefulness for diagnostics in clinical practice, may have adverse unwanted effects, ranging from a mild inconvenience, such as itching, to a life-threatening emergency [4].With the advent of nonionic, low-osmolality contrast media (LOCM) in the 1980s most adverse events are relatively mild and require no medical treatment [5] Among the side effects associated with the use of intravenous or intra-arterial injection of IRCA, Contrastinduced nephropathy (CIN) is undoubtedly their most important and frequent well known adverse reaction.
Other forms of adverse effects include delayed allergic reactions, anaphylactic reactions, and/or cutaneous reactions [6].
Previous allergic reactions to contrast material increase the risk of developing future adverse reactions to IRCA.In order to decrease the chance of allergic side effects, including anaphylaxis or a life-threatening emergency, pre-treatment of patients who have such risk factors with a corticosteroid and diphenhydramine has been suggested: either Prednisone (50 mg orally, 13, 7, and 1 hour before contrast injection), or Hydrocortisone (200 mg intravenously, 1 hour before contrast injection), or Methylprednisone (32 mg orally, 12 and 2 hours before contrast media injection); Diphenhydramine (50 mg intravenously/ intramuscularly/ orally Freely Available Online www.openaccesspub.org| JNA CC-license DOI : 10.14302/issn.2574-4488.jna-14-601 Vol-1 Issue 1 Pg.no.-8 Among the unwanted effects of IRCA, we have to mention hypersensitivity reactions.These may be: (a) mild, with an incidence <3%, consisting of immediate skin rashes, flushing or urticaria; (b) moderate to severe, with an incidence <0.04%, including angioedema, coronary artery spasm, hypotension, cardiac failure and loss of consciousness.Asthma, a history of multiple allergies and therapy with beta blockers increase the risk of bronchospasm.Mortality is less than one death per 100,000 patients.
As soon as a reaction occurs, the intravascular infusion of the contrast media must be ceased and treatment with antihistamine started.Bronchospasm and wheezing, laryngospasm and stridor or hypotension should be treated immediately with adrenaline, intravenous fluids and oxygen, in addition to antihistamines with or without hydrocortisone [8].
Other side effects of IRCA are the so-called 'Delayed adverse reactions' that are usually cutaneous (with an incidence reported from 1% to 23%) and include rash, skin redness, and skin swelling, sometimes associated with nausea, vomiting and dizziness; they

Contrast-Induced Thyroid Dysfunction
There has been little examination of the effect of IRCA on thyroid function in the scientific/medical literature.
Exposure to IRCA may be associated with development of either hyperthyroidism or hypothyroidism.This is presumably due to the effect of free, biologically active elemental iodine ions present in The terms iodine and iodide are often used interchangeably.Iodide refers to the metabolically important, non-organic free form that can be present in excess.A 200 ml dose of an IRCA containing 35 μg/mL iodine provides 7,000 μg free iodine, equivalent to 45 times the recommended daily intake [18].The dose of IRCA used in typical radiological procedure of medical practice contains approximately 13,500 μg of free iodide The iodinated radiographic contrast agents (IRCA)

Contrast-Induced Nephropathy (CIN)
The most important adverse unwanted effect of IRCA is undoubtedly the Contrast-Induced Nephropathy (CIN) also known as Contrast-Induced Acute Kidney Injury (CI-AKI).This is an Acute Renal Failure (ARF) occurring 24-72 hours after the exposure to  suggest an eGFR of 60 ml/min/1.73m

Measures for prevention of CIN
The first general rule when using IRCA for diagnostics or therapeutic procedures is that any patient should have his renal function measured before and after the procedure; in patients at high risk of CIN, SCr

Introduction
Iodinated radiographic contrast agents (IRCA) are commonly administered pharmaceutical agents very useful for improving the visibility of internal organs and structures (Iodine is an important element used in contrast media because it possesses high-contrast density) in X-ray based imaging techniques, such as radiography, angiography and contrast-enhanced computed tomography (CT) scans, and to perform cardiac catheterizations and percutaneous coronary interventions.They have been in use for over 60 years and their use for imaging and intravascular intervention keeps increasing, particularly in less healthy and older patients, with one or more comorbid conditions, such as advanced vascular disease, severe long-standing hypertension, diabetes and impairment of renal function [1].All currently used X-ray contrast media are based on the tri-iodinated benzene ring, acetrizoate being the parent tri-iodinated contrast medium first in clinical use [2].

begin 1
hour or longer (usually 6 to12 hours) after the administration of the contrast agent and are usually mild and non-life threatening (sometimes can be moderate to severe) and usually not brought to the attention of the radiologist and ascribed to other causes [9].Since patients are usually discharged from the radiology department within half an hour of contrast administration, these reactions are rarely observed by the radiologist.'Delayed adverse reactions' are significantly (p<0.05)more frequent with dimeric nonionic agents (16.4%) than with a monomeric nonionic agents (9.7%) [10].They vary in size and presentation, but are usually pruritic and self-limited; symptoms can be treated with corticosteroid creams.The pathophysiology of delayed cutaneous reactions is speculative, but likely represents a spectrum of T cellmediated delayed hypersensitivity [6].Previously, we have documented that both a single and/or a multidrug treatment, in particular clinical conditions, may be related to a higher development of adverse drug reactions (ADRs) and/or drug-drug interactions (DDIs) [11-16], and this represents a major issue during the clinical management of any disease requiring polytherapy.The same mechanisms involved in ADRs are determinant for adverse side effects observed after iodinated radiographic contrast agents.

Freely
Available Online www.openaccesspub.org| JNA CC-license DOI : 10.14302/issn.2574-4488.jna-14-601Vol-1 Issue 1 Pg.no.-9 the IRCA.It has been suggested that long storage and exposure to light of IRCA leads to photolytic degradation of contrast media, causing increase concentration of free elemental iodine in solution [17].

[ 18 ]
and 15 to 60g of bound iodine [3, 18] that may be liberated as free iodide in the body [19].This represents an acute iodide load of ninety to several hundred thousand times the recommended daily intake of iodide (150 μg) [20].Normally, the thyroid gland can regulate hormone synthesis and secretion in the presence of excessive amounts of iodine in the body.Iodine overload is accompanied by an autoregulatory phenomenon that inhibits thyroid hormone synthesis and release (Wolff-Chaikoff effect) [21].This effect is usually transient and lasts 8-10 days [22].After several days of exposure to high iodine levels, an 'escape phenomenon' occurs from the acute Wolf-Chaikoff effect, which is mediated by downregulation of the sodium iodide transporter (NIS) that transports iodine into the thyroid; thus, normal thyroid hormone production resumes [23, 24].Failure of the acute Wolff-Chaikoff effect results in iodineto escape from the acute Wolff-Chaikoff effect results in iodine-induced hypothyroidism [25, 26].Iodine-induced thyrotoxicosis after IRCA injection has been found in 7 of 28 cases of hyperthyroidism seen at a geriatric hospital [27].Several studies have demonstrated the occurrence of hyperthyroidism following nonionic contrast radiography [28].Hintze et al [29] have investigated the occurrence of iodine-induced thyrotoxicosis in unselected patients from an iodine-deficient geographic area undergoing coronary angiography.Thyroid hormone values and urinary iodine excretion were determined before, and 1, 4 and 12 weeks after IRCA injection.Two of 788 unselected patients developed hyperthyroidism within 12 weeks; both patients had normal TSH levels at baseline and ultrasound of the thyroid was without evidence of nodules.The Authors concluded that in euthyroid unselected patients from an iodine-deficient geographic area short-term iodine contamination by contrast media rarely leads to hyperthyroidism.Patients with pre-existing hyperthyroidism may develop a thyroid crisis.Patients with Graves' disease and multinodular goitre, especially elderly patients and patients living in areas of iodine deficiency, are at increased risk of developing thyrotoxicosis and should Vol-1 Issue 1 Pg.no.-10 receive iodinated contrast media only with close monitoring [8, 18].Patients with Hashimoto's thyroiditis or other autoimmune thyroid disease and patients, who have undergone partial thyroidectomy, are at risk for the development of iodine-induced hypothyroidism [24].Gartner and Weissel [30] have investigated the short-term effects of high doses of iodine (300-1221 mg of iodine per kilogram b.w.) on thyroid parameters in euthyroid patients.They measured serum concentrations of free triiodothyronine (FT3), free thyroxine (FT4), and thyrotropin (TSH) before and daily for 1 week after parenteral application of x-ray dyes (for coronary angiography or CT).TSH values increased significantly 3-5 days after the iodine load within the normal range with the exception of 4 patients (18%) who had a TSH increase above normal.FT4 and FT3 remained unchanged and there was no significant correlation between the dose of iodine and the TSH reaction.The Authors conclude that, even in euthyroid patients, the injection of IRCA, at the iodine dose ranging from 300 to 1221 mg of iodine per kilogram, can induce subclinical hypothyroidism.Rhee et al [26] have performed a nested casecontrol study to assess the association between the exposure to IRCA and incident thyroid dysfunction, using a database of patients receiving care at Brigham and Women's Hospital and at Massachusetts General Hospital in Boston, MA (USA).Incident hyperthyroidism was defined as a thyrotropin level, at follow-up, below the normal range, and incident hypothyroidism as a thyrotropin level above the normal range; incident overt hyperthyroidism was defined as a follow-up thyrotropin level <0.1 mIU/L and incident overt hypothyroidism as a follow-up thyrotropin level >10 mIU/L, based on evidence that such levels are associated with cardiovascular morbidity and mortality and are less likely to be due to non-thyroidal illness.They found a significant association between IRCA exposure and subsequent development of incident hyperthyroidism, incident overt hyperthyroidism, and incident overt hypothyroidism; no association was found between IRCA exposure and incident hypothyroidism.With widespread use of radiocontrast-enhanced imaging examinations, it is important for clinicians and radiologists to be aware of thyroid-specific complications [24].Iodine-induced hyperthyroidism is often difficult to treat, whereas iodine-induced hypothyroidism usually is self-limiting and resolves spontaneously [24].
their luminal diameter) by reducing NO and significantly increases the vasoconstrictor response to angiotensin II, thereby causing severe local hypoxia.Thus iodixanol, in doses typically used for coronary interventions, constricts medullary descending vasa recta, thereby causing severe medullary hypoxia.Medullary hypoxia may lead to the formation of reactive oxygen species (ROS) [78, 79] that (a) may exert direct tubular and vascular endothelial injury, (b) may intensify renal parenchymal hypoxia by virtue of endothelial dysfunction and dysregulation of tubular transport [80, 81], (c) may decrease NO synthesis that is believed to be due to its reaction with ROS, in particular superoxide anions (O 2 .-)[17, 82], leading to the formation of the more powerful oxidant peroxynitrite anion (ONOO -) [83].Sendeski et al [77] have demonstrated that the superoxide dismutase mimetic Tempol reduced iodixanol-induced vasoconstriction, thereby supporting the role of ROS.More recently Pisani et al. [84] have demonstrated that a recombinant manganese superoxide dismutase, administered in vivo to rats undergoing diatrizoate treatment, was able to reduce renal oxidative stress, thereby preventing the reduction of GFR and the renal histologic damage that follows IRCA administration.Patients with chronic renal failure (CRF) have defective antioxidant systems [85] and increased oxidative stress associated with inflammation and endothelial dysfunction [86].This may explain why pre-existing renal failure certainly represents the most common condition predisposing to the development of CIN.Thus, animal and human studies have clearly demonstrated that ROS generation is enhanced following IRCA administration, suggesting their important role in the pathogenesis of CIN [82].IRCA possess a cytotoxicity, that has been suggested to be due, at least in part, to the free iodine present in solutions of IRCA and that leads to apoptosis and cell death of both endothelial and tubular cells [17].The decrease in NO in the vasa recta may not be totally accounted for by increased ROS production; the damaged endothelial cells (including apoptosis) may be another important factor in decreasing NO; the decrease in NO production in the descending vasa recta, in fact, is partly due to a loss of endothelial cell viability caused by IRCA [17].On the other hand, the endothelial cells are the first to come in contact with intravenously-injected IRCA.The endothelial damage, represented by nuclear protrusion, cell shrinkage, fenestration of the endothelial layer and formation of microvilli ('blebbing') on the cell membrane, and cellular apoptosis have been observed by scanning electron microscopy [87].Endothelial damage may also release endothelin that causes vasoconstriction.Heyman et al [88] have in fact demonstrated that i.v.administration of contrast media in rats induced an increase in plasma concentration of Vol-1 Issue 1 Pg.no.-15 from cultured bovine endothelial cells.Reduced levels of prostaglandins have also been suggested to predispose to CIN [74].IRCA cause a direct damage also on the epithelial renal tubular cells [89].Once filtered by the glomeruli and concentrated in the renal tubules because of water reabsorption, in fact, they exert a direct injury to the renal tubular cells.The damage caused has been observed in isolated tubular segments and in cultured cells substantiated by disruption of cell integrity and apoptosis.This damage may be aggravated by factors, such as tissue hypoperfusion and hypoxia caused by IRCA and by clinically unfavourable conditions, such as pre-existing renal impairment particularly secondary to diabetic nephropathy, salt depletion and dehydration, congestive heart failure and concurrent use of nephrotoxic drugs [17, 32, 75, 90].The biochemical changes underlying the epithelial damage have been extended to study changes in major intracellular signalling pathways involved in cell survival, death and inflammation [79, 91-98] in vitro in cultured renal tubular cells [99].Recent studies have clarified these aspects in primary human tubular cells as well as in HK-2 cells exposed to different contrast media.Andreucci et al [96] demonstrated a decreased cell viability, secondary to a reduced activation of Akt/PKB and of ERK 1/2, both kinases known to play a pivotal role in cell survival/ proliferation, which was substantially alleviated by transfecting the HK-2 cells with a constitutively active form of Akt.The same Authors have demonstrated, in HK-2 cells, that contrast media affect the activation/ deactivation of transcription factors, like FoxO3a and STAT3, that control the genes involved in apoptosis and cell proliferation [95, 97].Studies in animals and in vitro studies suggest that IRCA can directly induce caspase-mediated apoptosis of renal tubular cells.Contrast-induced apoptosis may also be due to the activation of shock proteins and the concurrent inhibition of cytoprotective enzymes and prostaglandins [100, 101].Under physiological conditions, the Na + /Ca 2+ exchanger (NCX) can pump the Ca 2+ outside the renal tubular epithelial cells using the Na + concentration gradient across the cell membrane to keep a low intracellular Ca 2+ level.After IRCA injection, NCX may reversely extrude Na + for Ca 2+ influx and result in intracellular Ca 2+ overload that is considered to be an important factor in the pathogenesis of CIN [102, 103].At comparable iodine concentrations and x-ray attenuation, the non-ionic dimeric IRCA have about twice the viscosity of non-ionic monomeric IRCA [42-44].The concentration of the IRCA within the tubular lumen increases considerably because of tubular fluid reabsorption.The result will be a progressive increase in tubular fluid osmolality and, due to the exponential concentration-viscosity relationship, an overproportional increase in tubular fluid viscosity [44, 70].Since the Freely Available Online www.openaccesspub.org| JNA CC-license DOI : 10.14302/issn.2574-4488.jna-14-601Vol-1 Issue 1 Pg.no.-16 fluid flow rate through a tube increases with the pressure gradient and decreases with the flow resistance and since the resistance increases proportionally to fluid viscosity, the increased viscosity caused by IRCA increases the intratubular pressure [44].Thus, the osmotic diuresis caused by IRCA raises the intratubular pressure with a condition of tubular obstruction that contributes both to the tubular epithelial damage and to the fall of GFR [70].The effect of IRCA on morphology of erythrocytes has been also studied [104, 105].The formation of echinocytes and stomatocytes observed upon incubation of erythrocytes with IRCA may have a negative effect on the rheology of the blood [17].IRCA affect the membrane skeleton of erythrocytes, with iopromide causing drastic changes in the band3-spectrin network compared with iodixanol that may contribute to microcirculatory disorders (especially in patients with coronary artery disease) and gas transport, contributing to tissue hypo-oxygenation [106].Factors predisposing to CIN According to the European Society of Urogenital Radiology, patient conditions favoring CIN are represented by pre-existing renal impairment, particularly when associated with diabetes mellitus, salt depletion and dehydration, congestive heart failure, an age greater than 70 years and concurrent use of nephrotoxic drugs [107].Dehydration and salt depletion deserve a special discussion.Dehydration is the decrease of body water, as it occurs sometimes in old patients due to impaired sensation of thirst [108].But the term dehydration is frequently used to indicate salt and water depletion.Dehydration and salt depletion are responsible for the reduction of the 'effective' circulating blood volume, i.e. the relative fullness of the arterial tree as determined by cardiac output, peripheral vascular resistance and total blood volume [51].The most important risk factor for the development of CIN is undoubtedly the presence of renal insufficiency, irrespective of its cause.The lower the eGFR, the greater is the risk of CIN following the administration of IRCA.Mehran and Nikolski [57]

Freely 3 ]
Available Online www.openaccesspub.org| JNA CC-license DOI : 10.14302/issn.2574-4488.jna-14-601Vol-1 Issue 1 Pg.no.-19 and eGFR should be monitored before and once daily for 5 days after the radiographic procedure [59, 122].The second measure is that potentially nephrotoxic drugs (like aminoglycosides, vancomycin, amphotericin B, metformin and nonsteroidal antiinflammatory drugs) should be discontinued before the IRCA injection [122].The third measure is the choice of the least nephrotoxic radiocontrast agent.Iodixanol (IOCM) and iopamidol (LOCM) appear to be the IRCA of choice to reduce risk of CIN [123].The fourth precaution is to use the lowest dosage possible of IRCA.Before the advent of CT, IRCA were administered mainly for urography and angiography procedures.In the pre-CT era, most radiologists were utilizing 30-50 ml HOCM with hand injection rates of less than 1 ml/s for urography.The average IRCA dose for CT is approximately 100-150 ml with power injection rates of up to 3-4 ml/s [High doses of IRCA are actually required in coronary angiography and percutaneous coronary intervention.For these procedures, some formulas have been suggested to calculate the least dangerous dosage:(A) Cigarroa's formula: 5 mL of IRCA/kg b.w./SCr (mg/dL).The maximum dose acceptable is 300 mL for diagnostic coronary arteriography [124].(B) Laskey's formula: volume of IRCA to calculated creatinine clearance ratio with a cut-off point of the ratio at 3.7 [125]; a cut-off point of the ratio at 2.0 is better: below a ratio of 2.0, CIN would be a rare complication; but it would increase dramatically at a ratio of 3.0 [123, 126].(C) Ratio of grams of iodine to the calculated creatinine clearance; a ratio of 1.42, or even better a ratio of 1.0, would prevent CIN [123].The fifth and very important measure to prevent CIN is an adequate hydration of the patient [122, 127, 128].The old suggestion to limit fluid intake starting the day before contrast administration must be abolished.On the contrary, we have to give the patient a volume supplementation: e.g.500 mL of water orally before and 2,500 mL for 24 hours after IRCA administration to secure a urine output of at least 1 mL/ min [107].In high-risk patients the oral water load may be replaced by i.v.infusion of 0.9% saline at a rate of approximately 1 mL/kg b.w./hour, beginning 6-12 hours before and continuing for up to 12-24 hours after the radiographic examination (if urine output is appropriate and cardiovascular condition allows it) [59, 127].The purpose is to cause expansion of intravascular volume, to suppress renin-angiotensin cascade and consequently to reduce renal vasoconstriction and hypoperfusion.Furthermore, the resulting increase of urine output will limit the duration of IRCA contact with renal tubules and consequently its direct toxicity on renal tubular epithelium [129, 130].Freely Available Online www.openaccesspub.org| JNA CC-license DOI : 10.14302/issn.2574-4488.jna-14-601Vol-1 Issue 1 Pg.no.-20Some Authors have stated a preference for using sodium bicarbonate hydration that has been shown to be superior to sodium chloride in clinical studies and meta-analysis [131-139]: for coronary angiography or intervention 154-mEq/L infusion of sodium bicarbonate as a bolus of 3 mL/kg b.w./hour for 1 hour before the administration of IRCA, followed by 1 mL/kg/hour for 6 hours during and after the procedure has been used [132].The reason for using bicarbonate is the alkalinization of tubular fluid by bicarbonate that will reduce the production and increase the neutralization of oxygen free radicals, thereby protecting the kidney from injury by IRCA [134, 135, 140, 141].Others did not find any benefit with sodium bicarbonate hydration versus sodium chloride [142-145] or have even found an increased incidence of CIN [146].More recently, Brar et al [147] have stated the left ventricular enddiastolic pressure-guided fluid administration to be safe and effective in preventing CIN in patients undergoing cardiac catheterization.The European Renal Best Practice [148] position "recommends volume expansion with either isotonic sodium chloride or sodium bicarbonate solutions, rather than no volume expansion, in patients at increased risk for CIN" [148].We have mentioned that ROS may play an important role in the pathogenesis of CIN.Thus, antioxidants have been used to prevent CIN.The first antioxidant used for this purpose was N-acetylcysteine [149].Short-duration pretreatment with N-acetylcysteine has been shown to reduce IRCA-induced cytotoxicity in human embryonic kidney cells treated with the ionic HOCM ioxithalamate, non-ionic LOCM iopromide and the IOCM iodixanol [150] and to ameliorate the ischemic renal failure in animal models [151].The suggested dosage is 600 mg orally twice daily, the day before and the day of procedure [59] or, in patients unable to take the drug orally, an i.v.dose of 150 mg/kg over half an hour before the procedure or 50 mg/kg administered over 4 hours [152].But the protective effect of N-acetylcysteine against CIN in high risk patients is still controversial.Some studies have reported a protective effect [152-154], others have denied it [146, 155-161].Conflicting results have been obtained with the use of another antioxidant, ascorbic acid [150, 162-166].The suggested dosage is 3 g orally 2 hours before the procedure and 2 g during the night and in the morning after the procedure [162, 163].Jo et al [165] have found that N-acetylcysteine at a dose of 1,200 mg orally twice a day before and on the day of coronary catheterization, is more beneficial in preventing CIN than ascorbic acid, particularly in diabetic patients with renal insufficiency undergoing coronary angiography.Sadat et al [167] have carried out a metaanalysis with 1536 patients who completed the trial: Freely Available Online www.openaccesspub.org| JNA CC-license DOI : 10.14302/issn.2574-4488.jna-14-601Vol-1 Issue 1 Pg.no.-21 patients receiving ascorbic acid had a 33% less risk of developing CIN.The antioxidant vitamin E has been also used to prevent CIN.Tasanarong et al [168] have found that the oral administration of either 350 mg/day of αtocopherol or 300 mg/day of γ-tocopherol (5 days prior to the coronary procedure and continued for a further 2 days post-procedure) in combination with 0.9% saline (1 mL/kg/hour for 12 hours before and 12 hours after) is effective in protecting against CIN in patients with CRF undergoing coronary procedures with Iopromide (LOCM): CIN developed in 14.9% of cases in the placebo group, but only in 4.9% and 5.9% in the α-and γ-tocopherol groups, respectively.Nebivolol is a third-generation β 1 -adrenergic receptor antagonist [169, 170].It has been used to protect the kidney against CIN through its antioxidant and NO-mediated vasodilating action.Toprak et al [171] have performed an experimental study in rats and have found that nebivolol decreases medullary congestion, protein casts and tubular necrosis, systemic and renal oxidative stress, proteinuria secondary to IRCA, and that it increases the kidney nitrite level decreased by IRCA.Nebivolol has been used at a dosage of 5 mg/day for one week or 5 mg every 24 hours for 4 days demonstrating a decrease of the incidence of CIN in patients with renal dysfunction undergoing coronary angiography [172, 173].A protective effect of the active vitamin D analogue paricalcitol in the prevention of CIN has been demonstrated in an experimental model by Ari et al [174].In this study, Wistar albino rats were divided into 4 groups: control group, paricalcitol group, CIN group and paricalcitol plus CIN group.Paricalcitol was given intraperitoneally at a dose of 0.4 mg/kg per day (once daily) for 5 consecutive days.CIN was induced at day 4 by intravenous injection of indometacin (10 mg/kg; intravenously), followed after 15 min by Nv-nitro-Larginine methyl ester (L-NAME) 10 mg/kg and after further 15 min by 6 ml/kg high-osmolar radiological contrast agent meglumine amidotrizoate.The mean serum creatinine value was significantly lower (p<0.034)and the mean creatinine clearance value was significantly higher (p<0.042) in the "Paricalcitol plus CIN group" than in the "CIN group".Mean serum malondialdehyde (MDA) [175] levels, which are end products, together with kidney thiobarbituric acidreacting substances (TBARSs), of lipid peroxidation of membrane polyunsaturated fatty acids by free radicals and thereby indicators of oxidative damage, were also significantly lower in the "Paricalcitol plus CIN" group than in the CIN group (p<0.024).Similarly, mean TBARSs levels were significantly lower in the "Paricalcitol plus CIN group" than in the "CIN Group" (p<0.042).The increase in renal tissue and serum MDA levels and renal tissue TBARS levels by IRCA has been observed in experimental CIN models [171, 176, 177].In addition, injury in uremic rats, and aortic oxidative injury in atherosclerotic rats [178, 179] and also to attenuate cyclosporin A induced nephropathy by suppression of inflammatory and apoptotic factors through inhibition of some protein kinase-signalling pathways [180].Interestingly, Ari et al also showed that mean scores of tubular necrosis (p<0.024),proteinaceous casts (p<0.038),renal medullary congestion (p<0.035) and VEGF immunoexpression (p<0.018) in the "paricalcitol plus CIN group" were significantly lower than the ones obtained in the "CIN group".Thus, in their report the Authors conclude that paricalcitol causes a reduction in the unfavourable histopathological findings of CIN, possibly through its antioxidant effects by inhibition of lipid peroxidation and that, although further experimental and clinical studies are necessary, their findings provide evidence that paricalcitol has a significant potential as a therapeutic intervention for the prevention of CIN.Many studies have demonstrated a beneficial effect of statins to prevent CIN in patients undergoing percutaneous coronary intervention [181-186].On the other hand, hypercholesterolemia has been suggested as a predisposing factor to CIN.We have mentioned the study of Yang et al [120] demonstrating that long-term hypercholesterolemia in the rats is a risk factor for CIN.The nephroprotective effect of statins has been attributed to their antioxidant, anti-inflammatory, and antithrombotic properties and to their vasodilator property mediated by NO, that improves renal microcirculation [187, 188].Han et al [189] have demonstrated that rosuvastatin, at a dosage of 10 mg/day for five days, two days before, three days post the procedure, reduced the risk of CIN in patients with diabetes mellitus and chronic kidney disease undergoing coronary/peripheral arterial angiography.Al-Otaibi et al [187] have observed that simvastatin had a dose-dependent nephroprotective effect in experimental rats treated with IRCA.Patients on pravastatin had a lower incidence of CIN than patients on simvastatin [190, 191].Acikel et al [192] have demonstrated that shortterm atorvastatin (40 mg/day 3 days before the procedure) as well as chronic atorvastatin therapy had a protective effect on renal function after coronary angiography.In the study of Patti et al [193] patients undergoing percutaneous coronary intervention were given short-term pretreatment with atorvastatin (80 mg 12 hours before intervention with another 40-mg preprocedure, followed by long-term treatment of 40 mg/ day); this prevented CIN and shortened hospital stay.As we have mentioned in the Pathogenesis section above, outer medulla hypoxia is due (a) to low O 2 delivery for anatomical reasons and (b) to the high O 2 consumption due to the high active sodium reabsorption in the thick ascending limb of Henle' loop.Since IRCA cause increased delivery of tubular fluid to the thick ascending limb of Henle's loop, thereby increasing the active sodium reabsorption, it has been thought that furosemide, by decreasing sodium reabsorption in this tubular segment, would reduce medullary hypoxia, that is a crucial factor in the IRCA nephrotoxicity.But several studies have demonstrated no protection against CIN of this diuretic or even deleterious effects [194-196].Thus, diuretics should be avoided before contrast exposure [109].We have to mention, however, the Renal Guard system™ for the combined use of furosemide and hydration to prevent CIN [197, 198].In brief, as described by Briguori C. et al [198], this RenalGuard system™ would guide the physician in achieving high urine output with furosemide while simultaneously balancing urine output and venous fluid infusion to prevent hypovolemia.The device includes a closed-loop fluid management system, a high-volume fluid pump, a high accuracy dual weight measuring system, motiondetection artifact reduction, a single-use intravenous set and urine collection system that interfaces with a standard Foley catheter, real-time display of urine and replacement fluid volume, timely alerts to drain the urine bag or to replace the hydration fluid bag, and safety features such as automatic air and occlusion detection.However, additional studies are still necessary to define the role of RenalGuard therapy in preventing CIN, taking also into account both safety and cost-effectiveness.We have mentioned that after IRCA injection, NCX may reversely extrude Na + for Ca 2+ influx and result in intracellular Ca 2+ overload, that is believed to be a key factor in ischemic cell injury in CIN [102].Thus, calcium channel blockers have been hypothesized to have protective effects against CIN.But their use have given controversial results, protective for some Authors [199, 200], non protective according to others [89, 201]. ) in endemic goiter area: a 5 year follow-up.J Endocrinol Invest 12:239-44.26.Rhee CM, Bhan I, Alexander EK and Brunelli SM (2012) Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism.Arch Intern Med 172:153-9.doi: 10.1001/archinternmed.2011.67727.Martin FI, Tress BW, Colman PG and Deam DR (1993) Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly.Am J Med 95:78-82.28.Conn JJ, Sebastian MJ, Deam D, Tam M and Martin FI (1996) A prospective study of the effect of nonionic contrast media on thyroid function.Thyroid 6:107-10.29.Hintze G, Blombach O, Fink H, Burkhardt U and Kobberling J (1999) Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects.Eur J Endocrinol 140:264-7.30.Gartner W and Weissel M (2004) Do iodinecontaining contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week?Thyroid 14:521-4.doi: 10.1089/1050725041517075 31.Katzberg RW (1997) Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity.Radiology 204:297-312.32.Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B and Uder M (2005) Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro.Radiology 235:843-9.33.Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, Nephrotoxicity in High-Risk Patients Study of I-O and Low-Osmolar Non-Ionic Contrast Media Study I (2003) Nephrotoxic effects in high-risk patients undergoing angiography.N Engl J Med 348:491-9.doi: 10.1056/NEJMoa021833 34.Barrett BJ (1994) Contrast nephrotoxicity.J Am Soc Nephrol 5:125-37.35.Barrett BJ and Carlisle EJ (1993) Metaanalysis of the relative nephrotoxicity of high-and low-osmolality iodinated contrast media.Radiology 188:171-8.36.Taliercio CP, Vlietstra RE, Ilstrup DM, Burnett JC, Menke KK, Stensrud SL and Holmes DR, Jr. (1991) A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography.J Am Coll Cardiol 52. Andreucci VE, Fuiano G, Stanziale P and Andreucci M (1998) Role of renal biopsy in the diagnosis and prognosis of acute renal failure.Kidney Int Suppl 66:S91-5.53.Andreucci M, Federico S and Andreucci VE (2001) Edema and acute renal failure.Semin Nephrol 21:251-6.54.Curtis LM and Agarwal A (2007) HOpe for contrastinduced acute kidney injury.Kidney Int 72:907-9.doi: 10.1038/sj.ki.5002530 55.Weisbord SD and Palevsky PM (2008) Prevention of contrast-induced nephropathy with volume expansion.Clin J Am Soc Nephrol 3:273-80.doi: 10.2215/CJN.0258060756.Katzberg RW and Newhouse JH (2010) Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?Radiology 256:21-8.doi: 10.1148/ radiol.1009200057.Mehran R and Nikolsky E (2006) Contrast-induced nephropathy: definition, epidemiology, and patients at risk.Kidney Int Suppl:S11-5.doi: 10.1038/ sj.ki.5000368 58.Dong M, Jiao Z, Liu T, Guo F and Li G (2012) Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials.J Nephrol 25:290-301.doi:10.5301/jn.500006759.Gleeson TG and Bulugahapitiya S (2004) Contrastinduced nephropathy.AJR Am J Roentgenol 183:1673-89.doi: 10.2214/ajr.183.6.0183167360.Byrd L and Sherman RL (1979) Radiocontrastinduced acute renal failure: a clinical and pathophysiologic review.Medicine (Baltimore) 58:270-9.61.Campbell DR, Flemming BK, Mason WF, Jackson SA, Hirsch DJ and MacDonald KJ (1990) A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography.Can Assoc Radiol J 41:133-7.62. Gomes AS, Baker JD, Martin-Paredero V, Dixon SM, Takiff H, Machleder HI and Moore WS (1985) Acute renal dysfunction after major arteriography.ajr.145.6.124963.Harkonen S and Kjellstrand C (1981) Contrast nephropathy.Am J Nephrol 1:69-77.contrast material--induced nephropathy with intravenous administration.Radiology 243:622-8.doi: 10.1148/radiol.243306141165.Khoury GA, Hopper JC, Varghese Z, Farrington K, Dick R, Irving JD, Sweny P, Fernando ON and Moorhead JF (1983) Nephrotoxicity of ionic and nonionic contrast material in digital vascular imaging and selective renal arteriography.Br J Radiol 56:631 -5.66. Moore RD, Steinberg EP, Powe NR, Brinker JA, Fishman EK, Graziano S and Gopalan R (1992) Nephrotoxicity of high-osmolality versus lowosmolality contrast media: randomized clinical trial.Radiology 182:649-55.67.Deray G, Dubois M, Martinez F, Baumelou B, Beaufils H, Bourbouze R, Baumelou A and Jacobs C (1990) Renal effects of radiocontrast agents in rats: a new model of acute renal failure.Am J Nephrol 10:507-13.68. Bruce RJ, Djamali A, Shinki K, Michel SJ, Fine JP and Pozniak MA (2009) Background fluctuation of kidney function versus contrast-induced nephrotoxicity.AJR Am J Roentgenol 192:711-8.doi: 10.2214/ AJR.08.1413 69.Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM and Ellis JH (2013) Contrast materialinduced nephrotoxicity and intravenous lowosmolality iodinated contrast material.Radiology 267:94-105.doi: 10.1148/radiol.1212139470.Andreucci M, Faga T, Pisani A, Sabbatini M and Michael A (2014) Pathogenesis of Acute Renal Failure induced by iodinated radiographic contrast media.Austin J Nephrol Hypertens 1:1-6 id1005.71.Katzberg RW, Morris TW, Schulman G, Faillace RT, Boylan LM, Foley MJ, Spataro RF and Fischer HW (1983) Reactions to intravenous contrast media.Part I: Severe and fatal cardiovascular reactions in a canine dehydration model.Radiology 147:327-30.doi: 10.1148/radiology.147.2.6836112 72.Murphy SW, Barrett BJ and Parfrey PS (2000) Contrast nephropathy.J Am Soc Nephrol 11:177-82.73.Detrenis S, Meschi M, Musini S and Savazzi G (2005) Lights and shadows on the pathogenesis of contrastinduced nephropathy: state of the art.Nephrol Dial Transplant 20:1542-50.doi: 10.1093/ndt/gfh868 74.Heyman SN, Rosen S and Rosenberger C (2008) Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy.Clin J Am Soc Nephrol 3:288-96.doi: 10.2215/ CJN.02600607 75.Andreucci M (2014) Side effects of radiographic contrast media.Biomed Res Int 2014:872574.doi: 10.1155/2014/872574 76.Andreucci M, Faga T, Pisani A, Sabbatini M and Michael A (2014) Acute Kidney Injury by Radiographic Contrast Media: Pathogenesis and Prevention.BioMed Research Int 2014: 362725.doi: 10.1155/2014/362725.77.Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE and Persson PB (2009) Iodixanol, constriction of Freely Available Online www.openaccesspub.org| JNA CC-license DOI : 10.14302/issn.2574-4488.jna-14-601Vol-1 Issue 1 Pg.no.-30 medullary descending vasa recta, and risk for contrast medium-induced nephropathy.Radiology 251:697-704.doi: 10.1148/radiol.251308173278.Giaccia AJ, Simon MC and Johnson R (2004) The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease.Genes Dev 18:2183-94.doi: 10.1101/gad.124330479.Sabbatini M, Santillo M, Pisani A, Paterno R, Uccello F, Seru R, Matrone G, Spagnuolo G, Andreucci M, Serio V, Esposito P, Cianciaruso B, Fuiano G and Avvedimento EV (2006) Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury.Am J Physiol Renal Physiol 290:F1408-15.doi: 10.1152/ajprenal.00304.200580. Heyman SN, Rosen S, Khamaisi M, Idee JM and Rosenberger C (2010) Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy.Invest Radiol 45:188-95.doi: 10.1097/ RLI.0b013e3181d2eed8 81.Dawson P, Becker A and Holton JM (1983) The effect of contrast media on the growth of bacteria.Br J Radiol 56:809-15.82.Pisani A, Riccio E, Andreucci M, Faga T, Ashour M, Di Nuzzi A, Mancini A and Sabbatini M (2013) Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy.Biomed Res Int 2013:868321.doi: 10.1155/2013/868321 83.Pacher P, Beckman JS and Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease.A, Sabbatini M, Riccio E, Rossano R, Andreucci M, Capasso C, De Luca V, Carginale V, Bizzarri M, Borrelli A, Schiattarella A, Santangelo M and Mancini A (2014) Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury.Clin Exp Nephrol 18:424-31.doi: 10.1007/s10157-013-0828-2 85.Martin-Mateo MC, Sanchez-Portugal M, Iglesias S, de Paula A and Bustamante J (1999) Oxidative stress in chronic renal failure.Ren Fail 21:155-67.86.Okamura DM, Pennathur S, Pasichnyk K, Lopez-Guisa JM, Collins S, Febbraio M, Heinecke J and Eddy AA (2009) CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD.J Am Soc Nephrol 20:495-505.doi: 10.1681/ASN.200801000987.Gospos C, Freudenberg N, Staubesand J, Mathias K and Papacharlampos X (1983) The effect of contrast media on the aortic endothelium of rats.Radiology 147:685-8.doi: 10.1148/radiology.147.3.684460588.Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M and Epstein FH (1992) Radiocontrast agents induce endothelin release in vivo and in vitro.J Am Soc Nephrol 3:58-65.89.Caiazza A, Russo L, Sabbatini M and Russo D (2014) Hemodynamic and tubular changes induced by contrast media.Biomed Res Int 2014:578974.doi: 10.1155/2014/578974 90.Hardiek K, Katholi RE, Ramkumar V and Deitrick C Freely Available Online www.openaccesspub.org| JNA CC-license DOI : 10.14302/issn.2574-4488.jna-14-601Vol-1 Issue 1 Pg.no.-31(2001) Proximal tubule cell response to radiographic contrast media.Am J Physiol Renal Physiol 280:F61-70.91.Michael A, Faga T, Pisani A, Riccio E, Bramanti P, Sabbatini M, Navarra M and Andreucci M (2014) Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media.Biomed Res Int 2014:249810.doi: 10.1155/2014/249810 92.Andreucci M, Michael A, Kramers C, Park KM, Chen A, Matthaeus T, Alessandrini A, Haq S, Force T and Bonventre JV (2003) Renal ischemia/reperfusion and ATP depletion/repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHRL1.Kidney Int 64:1189-98.93.Andreucci M, Fuiano G, Presta P, Lucisano G, Leone F, Fuiano L, Bisesti V, Esposito P, Russo D, Memoli B, Faga T and Michael A (2009) Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. Cell Prolif 42:554-61.94.Andreucci M (2011) [Contrast media and nephrotoxicity: a molecular conundrum].G Ital Nefrol 28:355.95.Andreucci M, Lucisano G, Faga T, Bertucci B, Tamburrini O, Pisani A, Sabbatini M, Salzano S, Vitale M, Fuiano G and Michael A (2011) Differential activation of signaling pathways involved in cell death, survival and inflammation by radiocontrast media in human renal proximal tubular cells.Toxicol Sci 119:408-16.doi: 10.1093/toxsci/kfq332 96.Andreucci M, Fuiano G, Presta P, Esposito P, Faga T, Bisesti V, Procino A, Altieri V, Tozzo C, Memoli B and Michael A (2006) Radiocontrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells.Biochem Pharmacol 72:1334-42.97.Andreucci M, Faga T, Russo D, Bertucci B, Tamburrini O, Pisani A, Sabbatini M, Fuiano G and Michael A (2014) Differential activation of signaling pathways by low-osmolar and iso-osmolar radiocontrast agents in human renal tubular cells.J Cell Biochem 115:281-9.doi: 10.1002/jcb.2466298. Dawson P, Pitfield J and Skinnemoen K (1983) Isomeric purity and supersaturation of iopamidol.Br J Radiol 56:711-3.99.Andreucci M, Faga T, Lucisano G, Uccello F, Pisani A, Memoli B, Sabbatini M, Fuiano G and Michael A (2010) Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells.Chem Biol Interact 185:253-62.doi: 10.1016/j.cbi.2010.03.019 100.Cunha MA and Schor N (2002) Effects of gentamicin, lipopolysaccharide, and contrast media on immortalized proximal tubular cells.Ren Fail 24:687-90.101.Peer A, Averbukh Z, Berman S, Modai D, Averbukh M and Weissgarten J (2003) Contrast media augmented apoptosis of cultured renal mesangial, (2008) Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography.J Diabetes Complications 22:171-7.doi: 10.1016/j.jdiacomp.2006.11.002 114.Pflueger A, Larson TS, Nath KA, King BF, Gross JM and Knox FG (2000) Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus.Mayo Clin Proc 75:1275-83.doi: 10.4065/75.12.1275 115.Khamaisi M, Raz I, Shilo V, Shina A, Rosenberger C, Dahan R, Abassi Z, Meidan R, Lecht S and Heyman SN (2008) Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney.Kidney Int 74:91-100.doi: 10.1038/ ki.2008.112116.Rudnick MR, Goldfarb S and Tumlin J (2008) Contrast-induced nephropathy: is the picture any clearer?Clin J Am Soc Nephrol 3:261-2.doi: 10.2215/CJN.04951107117.Morabito S, Pistolesi V, Benedetti G, Di Roma A, Colantonio R, Mancone M, Sardella G, Cibelli L, Ambrosino M, Polistena F and Pierucci A (2012) Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography.J Nephrol 25:1098-107.doi: 10.5301/ jn.5000101 118.Morcos SK (1998) Contrast media-induced nephrotoxicity--questions and answers.Br J Radiol 71:357-65.119.Kolonko A, Kokot F and Wiecek A (1998) Contrast-associated nephropathy--old clinical problem and new therapeutic perspectives.Nephrol Dial Transplant 13:803-6.120.Yang D, Lin S, Yang D, Wei L and Shang W (2012)